U.S. Office REITs Stock News

Some Diamondback Energy, Inc. ( NASDAQ:FANG ) shareholders may be a little concerned to see that insider Lyndal Greth...

Potential SmartFinancial, Inc. ( NYSE:SMBK ) shareholders may wish to note that the Independent Director, Cathy...

We wouldn't blame SiTime Corporation ( NASDAQ:SITM ) shareholders if they were a little worried about the fact that...

Essent Group (ESNT) is back in focus after Keefe, Bruyette & Woods upgraded the stock to Outperform, following a Q1 2026 earnings report that exceeded market expectations on both revenue and earnings per share. See our latest analysis for Essent Group. At a share price of US$57.44, Essent Group has seen short term share price pressure, with the 30 day share price return down 9.01% and the year to date share price return down 11.18%. At the same time, the 1 year total shareholder return is...

In May 2026, Centuri Holdings, Inc. announced more than US$300 million in new commercial awards across gas, electric, and broader energy infrastructure services in the U.S. and Canada, mostly from new or expanded Master Services Agreements and new bid work. A key insight is that these awards lift Centuri’s year-to-date 2026 commercial wins to about US$1.70 billion and support an expected book-to-bill of roughly 1.2 times, highlighting solid conversion of its opportunity pipeline into...

Krispy Kreme, Inc. ( NASDAQ:DNUT ) shareholders (or potential shareholders) will be happy to see that the Director...

PolyPid Ltd. ( NASDAQ:PYPD ) is possibly approaching a major achievement in its business, so we would like to shine...

Some Lattice Semiconductor Corporation ( NASDAQ:LSCC ) shareholders may be a little concerned to see that the...

Anyone interested in Ziff Davis, Inc. ( NASDAQ:ZD ) should probably be aware that the Executive VP, Jeremy Rossen...

Gibraltar Industries (ROCK) is reshaping its business by divesting its Renewables segment. This move refocuses the company on its core Building Products and Structures segments amid shifting expectations around risk, growth and execution. See our latest analysis for Gibraltar Industries. The recent Renewables divestiture headlines come against a weak price backdrop, with the share price down 26.27% year to date and the 1-year total shareholder return down 38.83%. This suggests fading momentum...

The Morning Bull - US Market Morning Update Monday, Jun, 8 2026 US stock futures are pointing sharply lower this morning, with E mini S&P 500 contracts down about 2.6% and Nasdaq 100 futures off nearly 4.8%, as investors react to stronger than expected US jobs data and a jump in market volatility. Nonfarm payrolls rose by 172,000 in May and unemployment held at 4.3%, while wages grew 0.3% month over month, signaling a job market that is still firm and keeping alive the prospect of another...

Spire (SR) is back in focus after its latest second quarter update, where adjusted earnings came in slightly below estimates, revenue declined year over year, and management reset 2026 guidance alongside a new long term capital plan. See our latest analysis for Spire. Following the earnings reset and long term capital plan, Spire’s recent share price has been choppy, with the stock down over the past quarter but supported by a 1 year total shareholder return of 16.13% and a 5 year total...

If you are wondering whether CoStar Group at around US$33.89 is starting to look like value or still overpriced, the key is to understand what the current share price actually reflects. The stock is roughly flat over the last 7 days at up 0.1% and up 3.4% over the last 30 days, but the longer term picture is much weaker with the share price down 48.4% year to date and down 57.1% over the last 12 months. These declines sit against a backdrop of ongoing attention on CoStar Group's role in real...

Arcutis Biotherapeutics (ARQT) is back in focus after supporting a new American Journal of Clinical Dermatology manuscript that provides practical guidance on diagnosing and managing genital psoriasis across age groups, highlighting the company’s role in clinician education. See our latest analysis for Arcutis Biotherapeutics. Despite attention on the new genital psoriasis guidance and recent restricted stock unit grants, Arcutis Biotherapeutics’ share price, at US$21.23, has fallen sharply...

Why Evolution Metals & Technologies stock is on investors’ radar Evolution Metals & Technologies (EMAT) has drawn attention after a recent pullback, with the stock down about 30% over the past month and roughly 19% over the past 3 months. With a market value near US$4.0b, revenue of US$1.879m and a net loss of about US$1.0b, the company’s focus on critical materials and advanced manufacturing comes amid ongoing share price pressure. See our latest analysis for Evolution Metals &...

Qfin Holdings, Inc. recently reported first-quarter 2026 results showing revenue of CNY 3,909.33 million and net income of CNY 883.32 million, alongside second-quarter net income guidance of RMB 830–910 million. The company also announced that board member Mr. Dan Zhao resigned for personal reasons on June 3, 2026, leaving an eight-person board with six independent directors overseeing its AI-driven credit-tech operations. We’ll now examine how Qfin’s weaker first-quarter earnings and...

Why Pulse Biosciences is on investors’ radar Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 months that stand out against its recent trading history. See our latest analysis for Pulse Biosciences. Against this backdrop, the recent 32.76% 30-day share price return and 30.23% 90-day share price return sit alongside an 89.17% year-to-date share price gain and a 3-year total shareholder return of...

Why Uniti Group’s new fiber-backed debt deal matters for shareholders Uniti Group (UNIT) has priced about $1.14b of secured fiber network revenue term notes through subsidiary Kinetic ABS Issuer LLC, backed by residential fiber assets and customer agreements across multiple U.S. states. The company plans to use the proceeds for general corporate purposes, including capital expenditures and repayment of outstanding debt. This directly affects its capital structure, interest costs, and...

Perrigo recently reported past first-quarter 2026 results with adjusted earnings per share above estimates but revenue below expectations, citing softer consumer demand and inventory destocking, while it reaffirmed its full-year 2026 guidance. An interesting aspect is that management kept its outlook intact despite weaker sales trends and broadly lower analyst estimates, underscoring confidence in its current plan. We’ll now assess how Perrigo’s decision to reaffirm full-year guidance...

In early June 2026, USA Compression Partners, LP presented at Bank of America’s Energy & Power Credit Conference and RBC Capital Markets’ Global Energy, Power & Infrastructure Conference in New York, following first-quarter 2026 results that exceeded revenue expectations and reaffirmed full-year guidance. A key insight from these updates is how the J-W Power acquisition and tight compression market are supporting USA Compression’s utilization and contract visibility. Next, we’ll examine...

PureCycle Technologies (PCT) is back in focus after its Thailand subsidiary was admitted to the Thailand FastPass Investment Acceleration Program, tying the stock story more closely to its planned Rayong polypropylene recycling facility. See our latest analysis for PureCycle Technologies. The Thailand FastPass news lands after a sharp 112.84% 90 day share price return and a 31.32% 30 day share price return, even though the stock fell 10.29% on the day. A 26.67% 1 year total shareholder return...

Nuvalent, Inc. recently announced that the U.S. FDA accepted New Drug Applications for its investigational lung cancer therapies neladalkib and zidesamtinib, granting Priority Review to neladalkib and setting target action dates of September 18 and November 27, 2026, respectively. Together with the appointment of Georg Pirmin Meyer, M.D., as Chief International Officer, these milestones highlight Nuvalent’s push to build a global commercial footprint around its late-stage oncology...

Kodiak Sciences recently reported that its Phase III GLOW2 trial of Zenkuda for diabetic retinopathy met primary and key secondary endpoints with strong efficacy, and the company is also advancing multiple late-stage ophthalmology programs while maintaining a solid, debt-free balance sheet. This combination of positive late-stage data and an accelerated regulatory submission plan highlights how central Zenkuda has become to Kodiak’s overall pipeline story. Next, we’ll examine how Zenkuda’s...

In late April 2026, Weyerhaeuser reported Q1 results that topped expectations, with US$1.73 billion in net sales, US$77 million in adjusted net earnings, and completion of a US$192 million divestiture of 108,000 acres of non-core Virginia timberlands. Beyond the quarterly beat, the sale of lower-priority timberlands and progress in higher-margin Wood Products and Strategic Land Solutions highlight how Weyerhaeuser is reshaping its portfolio toward higher-return uses of its asset base. Next,...